Rising Prevalence and Technological Advancements Drive the Lymphedema Treatment Market

The “Global Lymphedema Treatment Market Size, Share, Growth Analysis, By End-User, By Product, By Condition Type, By Treatment Type – Industry Forecast 2023-2030” report has been added to ResearchAndMarkets.com’s offering.

The global lymphedema treatment market, valued at $786.53 million in 2021, is projected to grow significantly, reaching $1.74 billion by 2030. This robust growth is expected to occur at a Compound Annual Growth Rate (CAGR) of 9.5% during the forecast period of 2023-2030.

Lymphedema: A Growing Health Concern

Lymphedema, characterized by abnormal swelling due to a malfunctioning lymphatic system, primarily affects the lower extremities but can also impact the upper extremities and genitalia. It can result from various factors, including infections like filariasis and as a side effect of breast cancer treatment. Notably, lymphedema is estimated to affect 40% of breast cancer patients.

Market Drivers

Several factors are contributing to the growth of the lymphedema treatment market:

  1. Increasing Prevalence: The rising prevalence of lymphedema and breast cancer cases is a significant driver for the market. The condition can occur at any stage of cancer or following treatment, even years later.
  2. Product Innovation: Major industry players are introducing new products, driving demand for high-quality treatment options, and leveraging technological advancements to develop innovative solutions.
  3. Technological Advancements: Technological developments in lymphedema treatment methods are expected to accelerate market growth. These innovations are improving the effectiveness of treatment and enhancing patient outcomes.
  4. Government Initiatives: Supportive government programs and reimbursement policies are facilitating market growth by reducing the financial burden on patients and healthcare providers.

Challenges

Despite advancements, there is currently no permanent cure for lymphedema, posing a challenge to market growth. Additionally, the rising costs associated with procedures and treatments may limit market expansion.

Market Trends

Key trends driving market growth include the development of innovative and cutting-edge treatments to lower the risks associated with lymphedema. The expansion of the healthcare industry and increased healthcare innovation are also expected to fuel growth.

Segments Covered

The global lymphedema treatment market is segmented based on various factors, including end-user (hospitals, ambulatory surgical centers, specialty clinics, others), product (compression bandages, compression stockings, pneumatic compression devices, others), affected area (genital, lower extremity, upper extremity, others), age group (adult, geriatric), route of administration (oral, injectable, others), type (primary, secondary lymphedema), condition type (cancer, cardiovascular diseases, inflammatory diseases, others), treatment type (compression therapy, surgery, drug therapy, laser therapy, others), and region (North America, Europe, Asia-Pacific, South America, MEA).

Key Players

Leading companies in the global lymphedema treatment market include Bio Compression Systems, Tactile Medical, Medi, Lympha Press, Sigvaris, BSN Medical, L&R USA Inc., Devon Medical Products, 3M Health Care, JOBST USA, Thuasne, Wright Therapy Products, BioHorizons IPH, Inc., Haddenham Healthcare, ArjoHuntleigh, Paul Hartmann, Bioventus, Baxter International Inc., CircAid Medical Products, Inc., Essity Aktiebolag, and others.

For more information about this report visit https://www.researchandmarkets.com/r/wp2yyd

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.